Nasdaq Marketscompaniesinvestment opinion
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? (opens at Nasdaq Markets in a new tab)
Argenx's top and bottom lines are growing robustly, with 18 consecutive quarters of sales growth. The article questions whether the biotech stock remains underrated.
